NEO: Leadership change · Company disclosure

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On June 23, 2026, the Board of Directors (the "Board") of NeoGenomics, Inc. (the "Company") increased the size of the Board from nine to ten directors and appointed Carolyn S. Starrett as a director to fill the newly created vacancy, effective immediately. Ms. Starrett will serve as a member of the Board until the 2027 annual meeting of stockholders of the Company and until her successor is duly elected and qualified (or, if earlier, her resignation or removal). Ms. Starrett will receive compensation for her service as an independent director consistent with the Company's director compensation program as previously disclosed in the Company's definitive proxy statement for its 2026 annual meeting of stockholders. Item 7.01 Regulation FD Disclosure On June 25, 2026, the Company issued a press release regarding the appointment of Ms. Starrett to the Board, which is attached to the Current Report on Form 8-K as Exhibit 99.1. This information shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, and it shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing. Item 9.01 Financial Statements and Exhibits. (a) Not applicable (b) Not applicable (c) Not applicable (d) Exhibits. 99.1 Press Release of NeoGenomics, Inc. dated June 25, 2026 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURES Pursuant to the requirements of the